Literature DB >> 9733844

The Epstein-Barr virus immediate-early gene product, BRLF1, interacts with the retinoblastoma protein during the viral lytic cycle.

V L Zacny1, J Wilson, J S Pagano.   

Abstract

Retinoblastoma protein (Rb) is a key regulator of cellular proliferation, controlling entry into G1/S in the cell cycle, largely through its action in binding the cellular transcription factor E2F, which activates genes important in DNA synthesis. Small DNA tumor viruses encode gene products which can functionally inactivate Rb, promoting cellular proliferation and viral DNA synthesis. In this study, the Epstein-Barr virus (EBV) immediate-early lytic gene product, BRLF1 (R), is shown to bind Rb in vivo, shortly after induction of the viral lytic cycle in EBV-infected Akata cells. Furthermore, the temporal kinetics of R-Rb interaction correlate with displacement of E2F1 from Rb. Mapping of the domains required for the interaction of R and Rb proteins reveals that R binds specifically to the N terminus of Rb, outside the Rb pocket, and that the first 200 amino acids of R are required for this interaction. The interaction of R and Rb may initiate cell cycle progression and facilitate viral DNA synthesis during lytic replication.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733844      PMCID: PMC110141     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  79 in total

1.  Human cytomegalovirus stimulates host cell RNA synthesis.

Authors:  S Tanaka; T Furukawa; S A Plotkin
Journal:  J Virol       Date:  1975-02       Impact factor: 5.103

Review 2.  Interaction of adenoviral proteins with pRB and p53.

Authors:  E Moran
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

Review 3.  DP and E2F proteins: coordinating transcription with cell cycle progression.

Authors:  E W Lam; N B La Thangue
Journal:  Curr Opin Cell Biol       Date:  1994-12       Impact factor: 8.382

Review 4.  The retinoblastoma tumor suppressor protein.

Authors:  J Y Wang; E S Knudsen; P J Welch
Journal:  Adv Cancer Res       Date:  1994       Impact factor: 6.242

5.  An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators.

Authors:  M A Cox; J Leahy; J M Hardwick
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

6.  Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7.

Authors:  G A Parker; T Crook; M Bain; E A Sara; P J Farrell; M J Allday
Journal:  Oncogene       Date:  1996-12-19       Impact factor: 9.867

Review 7.  Transcriptional control by E2F.

Authors:  P D Adams; W G Kaelin
Journal:  Semin Cancer Biol       Date:  1995-04       Impact factor: 15.707

8.  Transactivation by the human cytomegalovirus IE2 86-kilodalton protein requires a domain that binds to both the TATA box-binding protein and the retinoblastoma protein.

Authors:  M H Sommer; A L Scully; D H Spector
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

9.  Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.

Authors:  P R Yew; A J Berk
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

10.  Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein.

Authors:  C Hagemeier; R Caswell; G Hayhurst; J Sinclair; T Kouzarides
Journal:  EMBO J       Date:  1994-06-15       Impact factor: 11.598

View more
  25 in total

Review 1.  Participation of recombination proteins in rescue of arrested replication forks in UV-irradiated Escherichia coli need not involve recombination.

Authors:  J Courcelle; P C Hanawalt
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

Review 2.  Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products.

Authors:  C Swanton; N Jones
Journal:  Int J Exp Pathol       Date:  2001-02       Impact factor: 1.925

3.  Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites.

Authors:  T Ragoczy; G Miller
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 4.  Herpesvirus lytic replication and the cell cycle: arresting new developments.

Authors:  E K Flemington
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

5.  Disruption of gammaherpesvirus 68 gene 50 demonstrates that Rta is essential for virus replication.

Authors:  Iglika V Pavlova; Herbert W Virgin; Samuel H Speck
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

6.  Characterization and cell cycle regulation of the major Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent genes and their promoter.

Authors:  R Sarid; J S Wiezorek; P S Moore; Y Chang
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

7.  Role of RNF4 in the ubiquitination of Rta of Epstein-Barr virus.

Authors:  Ya-Chun Yang; Yushi Yoshikai; Shih-Wei Hsu; Hisato Saitoh; Li-Kwan Chang
Journal:  J Biol Chem       Date:  2013-03-15       Impact factor: 5.157

8.  Open reading frame 50 protein of Kaposi's sarcoma-associated herpesvirus directly activates the viral PAN and K12 genes by binding to related response elements.

Authors:  Pey-Jium Chang; Duane Shedd; Lyn Gradoville; Myung-Sam Cho; Lee-Wen Chen; Jimmy Chang; George Miller
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

9.  Two phenylalanines in the C-terminus of Epstein-Barr virus Rta protein reciprocally modulate its DNA binding and transactivation function.

Authors:  Lee-Wen Chen; Vineetha Raghavan; Pey-Jium Chang; Duane Shedd; Lee Heston; Henri-Jacques Delecluse; George Miller
Journal:  Virology       Date:  2009-02-15       Impact factor: 3.616

10.  Comparative study of regulation of RTA-responsive genes in Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8.

Authors:  Moon Jung Song; Hongyu Deng; Ren Sun
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.